Crescendo Bioscience Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
131
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$270M
Crescendo Bioscience General Information
Description
Operator of a molecular diagnostics company focused in rheumatology. The company is focused on developing and commercializing quantitative blood tests for rheumatoid arthritis (RA), including Vectra DA, a standardized multi-biomarker blood test validated to assess disease activity in RA, enabling effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients.
Contact Information
Website
www.crescendobio.comCorporate Office
- 341 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 341 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Crescendo Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 28-Feb-2014 | $270M | Completed | Generating Revenue | ||
| 6. Debt - General | 01-Jul-2013 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 31-Dec-2012 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 08-Sep-2011 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 07-Jul-2010 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 05-Mar-2007 | $5.08M | $5.08M | Completed | Product Development | |
| 1. Early Stage VC | 15-Jun-2006 | Completed | Startup |
Crescendo Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 9,683,593 | $0.010000 | $0.31 | $3.92 | $3.92 | 1x | $3.92 | 12.91% |
| Series A | 1,954,655 | $0.010000 | $0.21 | $2.6 | $2.6 | 1x | $2.6 | 2.61% |
Crescendo Bioscience Comparisons
Industry
Financing
Details
Crescendo Bioscience Competitors (26)
One of Crescendo Bioscience’s 26 competitors is Foundation Medicine, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Akonni Biosystems | Venture Capital-Backed | Frederick, MD | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA | ||||
| Epic Sciences | Venture Capital-Backed | San Diego, CA | ||||
| Biodesix | Formerly VC-backed | Louisville, CO |
Crescendo Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Crescendo Bioscience Patents
Crescendo Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024161429-A | Methods for cardiovascular disease in rheumatoid arthritis | Pending | 13-Mar-2019 | ||
| JP-2023145708-A | Biomarkers and methods for assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients | Pending | 14-Sep-2017 | ||
| JP-2021092573-A | Biomarkers and methods for assessing psoriatic arthritis disease activity | Active | 29-Sep-2015 | ||
| JP-2023010789-A | Biomarkers and methods for assessing disease activity in psoriatic arthritis | Active | 29-Sep-2015 | ||
| CA-2950771-A1 | Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity | Inactive | 10-Jun-2014 | G16B20/20 |
Crescendo Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Crescendo Bioscience Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Barclays UK Ventures | Corporate Venture Capital | Minority | ||
| Calibrium (Zurich) | Family Office | Minority | ||
| Fjord Ventures | Venture Capital | Minority | ||
| Kleiner Perkins | Venture Capital | Minority | ||
| Mohr Davidow Ventures | Venture Capital | Minority |
Crescendo Bioscience FAQs
-
When was Crescendo Bioscience founded?
Crescendo Bioscience was founded in 2002.
-
Where is Crescendo Bioscience headquartered?
Crescendo Bioscience is headquartered in South San Francisco, CA.
-
What is the size of Crescendo Bioscience?
Crescendo Bioscience has 131 total employees.
-
What industry is Crescendo Bioscience in?
Crescendo Bioscience’s primary industry is Biotechnology.
-
Is Crescendo Bioscience a private or public company?
Crescendo Bioscience is a Private company.
-
What is the current valuation of Crescendo Bioscience?
The current valuation of Crescendo Bioscience is .
-
What is Crescendo Bioscience’s current revenue?
The current revenue for Crescendo Bioscience is .
-
How much funding has Crescendo Bioscience raised over time?
Crescendo Bioscience has raised $143M.
-
Who are Crescendo Bioscience’s investors?
Barclays UK Ventures, Calibrium (Zurich), Fjord Ventures, Kleiner Perkins, and Mohr Davidow Ventures are 5 of 10 investors who have invested in Crescendo Bioscience.
-
Who are Crescendo Bioscience’s competitors?
Foundation Medicine, Akonni Biosystems, Guardant Health, Epic Sciences, and Biodesix are some of the 26 competitors of Crescendo Bioscience.
-
When was Crescendo Bioscience acquired?
Crescendo Bioscience was acquired on 28-Feb-2014.
-
Who acquired Crescendo Bioscience?
Crescendo Bioscience was acquired by Myriad Genetics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
